9-nitro-20-O-camptothecin propionate

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 喜树碱
• 英文名称: 9-nitro-20-O-camptothecin propionate
• 英文别名: CZ112；9-nitrocamptothecin-20-O-propionate；[(19S)-19-ethyl-8-nitro-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] propanoate
• 化学式: C₂₃H₁₉N₃O₇
• 分子量: 449.42
• InChiKey: DWWLEJVEBYDPHM-QHCPKHFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  132
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  鲁比替康 在 吡啶 作用下， 以 丙酸酐 、 Petroleum ether 为溶剂， 以73%的产率得到9-nitro-20-O-camptothecin propionate
  参考文献：
  名称：

  Liposomal prodrugs comprising derivatives of camptothecin and methods of

  摘要：

  脂质体前药包括由脂质体传递系统限制的喜树碱的特定衍生物。喜树碱的衍生物由下式表示：##STR1## 其中当R.sub.2为H时，R.sub.1为C.sub.2-C.sub.4烷基，C.sub.6-C.sub.15烷基，C.sub.3-C.sub.8环烷基，C.sub.2-C.sub.15烯基或C.sub.2-C.sub.15环氧基；当R.sub.2为硝基时，R.sub.1为C.sub.1-C.sub.15烷基，C.sub.2-C.sub.15烯基，C.sub.3-C.sub.8环烷基或环氧基。还公开了制造这些前药和在癌症治疗中使用它们的方法。

  公开号：

  US06096336A1

文献信息

• Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
  申请人：The Stehlin Foundation For Cancer Research

  公开号：US06352996B1

  公开（公告）日：2002-03-05

  Derivatives of camptothecin as represented by the general formula: are described, wherein when R1 is H, R. is a C2-C4 alkyl group, a C6-C15 alkyl group, a C3-C8 cycloalkyl group, a C2-C15 alkenyl group or a C2-C15 epoxy group; and when R2 is a nitro group or an amino group, R1 is a C1-C15 alkyl group, a C1-C15 alkenyl group, a C3-C8 cycloalkyl group, or an epoxy group. Liposomal prodrugs including these specific derivatives of camptothecin restrained by a liposomal delivery system are also described. Processes for making these prodrugs and for using them in cancer treatment are also disclosed.

  通用公式所代表的紫杉醇衍生物如下所述： 其中当R1为H时，R为C2-C4烷基、C6-C15烷基、C3-C8环烷基、C2-C15烯基或C2-C15环氧基；当R2为硝基或氨基时，R1为C1-C15烷基、C1-C15烯基、C3-C8环烷基或环氧基。还描述了包括这些特定紫杉醇衍生物的脂质体前药，其受限于脂质体传递系统。还公开了制备这些前药以及在癌症治疗中使用它们的方法。
• Alternating treatment with topoisomerase I and topoisomerase II inhibitors
  申请人：——

  公开号：US20040204435A1

  公开（公告）日：2004-10-14

  A method to treat cancer is described which involves alternating treatments with a topoisomerase-I inhibitor and a topoisomerase-II inhibitor. Other aspects of the invention are further described.

  本发明描述了一种治疗癌症的方法，包括交替使用拓扑异构酶-I 抑制剂和拓扑异构酶-II 抑制剂进行治疗。对本发明的其他方面作了进一步描述。
• Alkyl Esters of Camptothecin and 9-Nitrocamptothecin:  Synthesis, in Vitro Pharmacokinetics, Toxicity, and Antitumor Activity
  作者：Zhisong Cao、Nick Harris、Anthony Kozielski、Dana Vardeman、John S. Stehlin、Beppino Giovanella

  DOI：10.1021/jm9607562

  日期：1998.1.1

  Eleven camptothecin esters, 6a-e and 7a-f, were prepared by straightforward acylation of camptothecins with the corresponding acylating reagents such as organic anhydrides and carboxylic acid chlorides. The in vitro pharmacokinetic determination of lactone levels of esters 6a and 7b showed that the biological life span of their lactone forms in human and mouse plasma significantly increased when compared with their mother compounds, camptothecin (3) and 9-nitrocamptothecin (4). The differences of lactone levels between human plasma and mouse plasma for 6a and 7b were much smaller than what was observed for their mother compounds. The in vivo antitumor activity and toxicity studies demonstrated that some of these esters were very active against human tumor xenografts in nude mice and had an exceptional lack of toxicity in nude mice, even at enormous doses.
• [EN] ALTERNATING TREATMENT OF CANCER WITH TOPOISOMERASE I AND TOPOISOMERASE II INHIBITORS<br/>[FR] TRAITEMENT DU CANCER ALTERNANT DES INHIBITEURS DE TOPOISOMERASE I ET DES INHIBITEURS DE TOPOISOMERASE II
  申请人：STEHLIN FOUNDATION FOR CANCER

  公开号：WO2004091621A1

  公开（公告）日：2004-10-28

  A method to treat cancer is described which involves alternating treatments with a topoisomerase-I inhibitor and a topoisomerase-II inhibitor. Other aspects of the invention are further described.
• Liposomal prodrugs comprising derivatives of camptothecin and methods of
  申请人：The Stehlin Foundation for Cancer Research

  公开号：US06096336A1

  公开（公告）日：2000-08-01

  Liposomal prodrugs include specific derivatives of camptothecin restrained by a liposomal delivery system. The derivatives of camptothecin are represented by the general formula: ##STR1## wherein when R.sub.2 is H, R.sub.1 is a C.sub.2 -C.sub.4 alkyl group, a C.sub.6 -C.sub.15 alkyl group, a C.sub.3 -C.sub.8 cycloalkyl group, a C.sub.2 -C.sub.15 alkenyl group or a C.sub.2 -C.sub.15 epoxy group; and when R.sub.2 is a nitro group, R.sub.1 is a C.sub.1 -C.sub.15 alkyl group, a C.sub.2 -C.sub.15 alkenyl group, a C.sub.3 -C.sub.8 cycloalkyl group, or an epoxy group. Processes for making these prodrugs and for using them in cancer treatment are also disclosed.

  脂质体前药包括由脂质体传递系统限制的喜树碱的特定衍生物。喜树碱的衍生物由下式表示：##STR1## 其中当R.sub.2为H时，R.sub.1为C.sub.2-C.sub.4烷基，C.sub.6-C.sub.15烷基，C.sub.3-C.sub.8环烷基，C.sub.2-C.sub.15烯基或C.sub.2-C.sub.15环氧基；当R.sub.2为硝基时，R.sub.1为C.sub.1-C.sub.15烷基，C.sub.2-C.sub.15烯基，C.sub.3-C.sub.8环烷基或环氧基。还公开了制造这些前药和在癌症治疗中使用它们的方法。